News
NAMS
33.82
-1.80%
-0.62
NewAmsterdam Pharma: Undervalued Growth Story With Upcoming Clinical Catalysts Supporting Buy Rating
TipRanks · 1d ago
Weekly Report: what happened at NAMS last week (0406-0410)?
Weekly Report · 2d ago
Weekly Report: what happened at NAMS last week (0330-0403)?
Weekly Report · 04/06 10:20
NewAmsterdam Pharma Company (NAMS) Receives a Buy from Wells Fargo
TipRanks · 04/02 11:45
Weekly Report: what happened at NAMS last week (0323-0327)?
Weekly Report · 03/30 10:20
Weekly Report: what happened at NAMS last week (0316-0320)?
Weekly Report · 03/23 10:16
NewAmsterdam Pharma initiated with a Buy at Truist
TipRanks · 03/18 19:50
AMG TimesSquare Small Cap Growth Fund Q4 2025 Performance Insights
Seeking Alpha · 03/18 05:35
Weekly Report: what happened at NAMS last week (0309-0313)?
Weekly Report · 03/16 10:16
NewAmsterdam Pharma Director Makes Major Stock Move in High-Value Sale
TipRanks · 03/13 02:08
Weekly Report: what happened at NAMS last week (0302-0306)?
Weekly Report · 03/09 10:16
Massive Insider Move at NewAmsterdam Pharma Shakes Up Investor Buzz
TipRanks · 03/03 02:10
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation
TipRanks · 03/02 13:43
Weekly Report: what happened at NAMS last week (0223-0227)?
Weekly Report · 03/02 10:15
Top Executive Makes Bold Move With Major NewAmsterdam Pharma Stock Sale
TipRanks · 02/25 02:06
Interesting NAMS Put And Call Options For July 17th
NASDAQ · 02/23 15:40
Weekly Report: what happened at NAMS last week (0216-0220)?
Weekly Report · 02/23 10:15
Reaffirming Buy on NewAmsterdam Pharma: Optimized Expense Outlook and Milestone Upside Strengthen Risk‑Reward Profile
TipRanks · 02/21 01:45
NewAmsterdam Pharma Is Maintained at Buy by Guggenheim
Dow Jones · 02/19 14:42
NewAmsterdam Pharma Price Target Raised to $45.00/Share From $41.00 by Guggenheim
Dow Jones · 02/19 14:42
More
Webull provides a variety of real-time NAMS stock news. You can receive the latest news about NewAmsterdam Pharma Company N.V through multiple platforms. This information may help you make smarter investment decisions.
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.